title: Delivery of antibiotics to the eye using a positively charged polysaccharide as vehicle.
abstract: The positively charged polysaccharide chitosan is able to increase precorneal residence time of ophthalmic formulations containing active compounds when compared with simple aqueous solutions. The purpose of the study was to evaluate tear concentration of tobramycin and ofloxacin after topical application of chitosan-based formulations containing 0.3% wt/vol of antibiotic and to compare them with 2 commercial solutions: Tobrex and Floxal, respectively. The influence of the molecular weight, deacetylation degree, and concentration of 4 different samples of chitosan on pharmacokinetic parameters (area under the curve values [AUC(eff)] and time of efficacy [t(eff)]) of tobramycin and ofloxacin in tears was investigated over time. It was demonstrated that the 2 chitosan products of high molecular weight (1350 and 1930 kd) and low deacetylation degree (50%) significantly increased antibiotic availability when compared to the controls, with AUC(eff) showing a 2- to 3-fold improvement. The time of efficacy of ofloxacin was significantly increased from about 25 minutes to 46 minutes by the chitosan of higher Mw (1930 kd) at a concentration of 0.5% wt/vol, whereas a similar performance was achieved by a chitosan of low Mw (580 kd) at a concentration of 1.5% wt/vol in the case of tobramycin.
authors.affiliation: School of Pharmacy, University of Geneva, CH-1211 Geneva 4, Switzerland.
authors.forename: O
authors.initials: O
authors.lastname: Felt
authors.forename: V
authors.initials: V
authors.lastname: Baeyens
authors.forename: P
authors.initials: P
authors.lastname: Buri
authors.forename: R
authors.initials: R
authors.lastname: Gurny
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D001682:Biological Availability; D001704:Biopolymers / Q000008:administration & dosage / Q000737:chemistry; D002686:Chitin / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000737:chemistry*; D048271:Chitosan; D004304:Dosage Forms; D016503:Drug Delivery Systems / Q000379:methods*; D005123:Eye / Q000378:metabolism*; D008297:Male; D015394:Molecular Structure; D008970:Molecular Weight; D015242:Ofloxacin / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D011817:Rabbits; D012995:Solubility; D012996:Solutions / Q000737:chemistry; D013666:Tears / Q000737:chemistry; D013997:Time Factors; D014031:Tobramycin / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D001704:Biopolymers; D004304:Dosage Forms; D012996:Solutions; D002686:Chitin; D048271:Chitosan; D015242:Ofloxacin; D014031:Tobramycin